When considering who should be transplanted for acute myeloid leukemia (AML), it may be useful to consider four categories of patients. First, there are those who fail to achieve an initial remission with primary induction chemotherapy. Second, there are patients who achieve an initial complete remission, but subsequently relapse. Third are patients in first complete remission. Finally, there may be patients with AML who should be transplanted at diagnosis without first undergoing standard induction therapy.
Several studies have demonstrated that long-term survival is possible if patients who fail initial induction chemotherapy are then transplanted. For example, the European Bone Marrow Transplant Group reported 20% long-term survival with matched sibling transplantation in such patients. 1 Similarly, there are now data that some patients who receive unrelated donor transplants as therapy for primary induction failure can still be cured. In order to improve the probability that patients who fail primary induction have an opportunity to be transplanted, HLA typing of patient and family members soon after initial diagnosis should be strongly considered. Undoubtedly, lives have been lost because physicians have neglected or delayed the process of searching for an appropriate donor until it is too late.
The chance of cure for patients who relapse after an initial remission is very small if retreated with chemotherapy. Patients who have very long durations of first remission and favorable cytogenetics have the greatest likelihood of cure with salvage chemotherapy, 2 but such patients are uncommon and the vast majority of patients who relapse after an initial remission should be considered for transplantation. Whether patients with AML in first relapse should be reinduced prior to undergoing transplantation is a difficult question. Several studies have documented 25-30% cure rates for patients transplanted at first relapse without reinduction. 3, 4 Although the cure rate for transplantation in second remission may be slightly higher, reinduction chemotherapy is only successful in roughly 50% of the patients and 15-20% of patients will die during attempted reinduction with most regimens. Thus, the aggregate cure rate with reinduction followed by transplantation may be no higher than going straight to transplant. No study has directly tested this question. However, not all patients in first relapse do well with transplantation. Patients with circulating blasts do less well than patients whose blasts are confined to the marrow. Our general philosophy in Seattle is that if relapse is diagnosed before patients have substantial numbers of circulating blasts and the transplant can be initiated promptly, we would proceed directly to transplant in untreated first relapse. However, if patients have circulating blasts or if time is required to identify a donor, arrange financing, or secure a transplant bed, we would generally recommend reinduction.
No prospective study has addressed the optimal source of stem cells for second remission transplants. The EBMT performed a matched cohort analysis comparing matched sibling transplantation with autologous transplantation and found that the outcome with matched sibling transplantation was superior for patients in second remission. 5 The patients included in the two arms were matched for cytogenetic risk group, age, and duration of first remission. Similarly, the same group performed a cohort analysis comparing outcome of autologous transplantation with unrelated donor transplants. 6 Again, those performing the analysis attempted to match the two groups for important risk factors. Long-term survival in the two groups was not significantly different and in both groups, 35-45% of patients were apparently cured. In making the decision of which source of stem cells to use, patient and disease factors probably should be taken into consideration. Younger patients with a short first remission and with unfavorable cytogenetics may do better with unrelated donor transplantation, whereas older patients who have had a long duration of first remission and more favorable cytogenetics might do well with an autologous transplant and, thus, this approach would be favored given its lower morbidity.
The most difficult question is the issue of who to transplant in first remission. This is a question that will continually be asked because outcomes of chemotherapy and transplantation change as these therapies evolve. There have been four large studies that have attempted to address which modality is better by identifying patients at diagnosis and then assigning patients in first remission to allogeneic transplantation if they have a matched sibling donor, and randomizing the remaining patients to consolidation chemotherapy or autologous transplantation. The first by the EORTC showed a statistically significant advantage for 4-year disease-free survival for autologous and allogeneic marrow transplantation over standard chemotherapy. 7 The studies by ECOG/SWOG and GOELAM found no significant differences in disease-free survival with these three approaches. 8, 9 Burnett et al 10 for the MRC reported a statistically significant advantage in disease-free survival for autologous transplantation compared to chemotherapy.
Each of these four studies differed somewhat in their structure. In the EORTC study, patients were induced into remission, then received consolidation chemotherapy with moderately high-dose cytarabine plus an anthracycline and then were treated with allogeneic or autologous transplantation vs a second course of intensive consolidation chemotherapy. In the MRC study, patients received three cycles of intensive consolidation chemotherapy and then were randomized to autologous transplantation or to no further therapy. In the ECOG/SWOG study, patients were induced with idarubicin and cytarabine followed by relatively low-dose consolidation with idarubicin and 5 days of cytarabine.
Patients were then allocated to allogeneic transplantation if they had an HLA-identical sibling or randomized between autologous transplantation vs a single cycle of high-dose cytarabine. Thus, one major difference in the two studies that showed a clear advantage for autologous transplantation is that, in both, patients received intensive consolidation chemotherapy before proceeding to transplantation, whereas in the ECOG/SWOG study they did not.
All four studies have real limitations. First, none prospectively accounted for salvage strategies. In patients with matched siblings, the issue is not whether transplantation is better than chemotherapy, but whether transplantation in first remission is better or worse than chemotherapy followed by transplantation at first relapse. None of the studies addressed this question. A second limitation is that all of the studies were based on an intent-to-treat analysis and up to 45% of the patients allocated to the autologous transplant arm did not receive the transplant, whereas 90-95% of those allotted to the chemotherapy arms received their assigned treatment. The intent-to-treat analysis dilutes any effect of transplantation on outcome. A third issue is that these studies are describing results with chemotherapy and transplant regimens that were designed more than a decade ago. Inevitably, it takes a considerable amount of time to initiate such large studies, accrue adequate patients, allow for sufficient follow-up, collect the data, and publish the results. Important advances in these treatments may have occurred during this interval. For example, in Seattle we are asking whether the use of radiolabeled antibodies to target radiotherapy to marrow can improve the outcome of allogeneic transplantation. In our study, we have combined targeted radiotherapy with a busulfan/ cyclophosphamide preparative regimen and have achieved a 75% disease-free survival in the first 37 patients studied, many of whom had unfavorable cytogenetics. 11 Similarly, the group from Sloan-Kettering has published results with better than 70% survival in AML patients transplanted in first remission using a strategy of intensive chemo-radiotherapy followed by lectin based T cell-depleted marrow transplantation. 12 A final shortcoming of these studies is that they considered all AML patients as being equivalent, whereas we know that there are substantial differences in the biology of the disease, as well as patients' tolerance to treatment. Thus, there may be important differential effects of transplantation in first remission among subgroups of patients. Unfortunately, the reality is that once patients are assigned to individual cytogenetic risk groups and then different therapies are analyzed in each, the number of patients in each category becomes small making such studies very difficult. When one further considers patients' specific characteristics such as age and CMV serotype, studies with real statistical power become almost impossible to conduct. Nonetheless, both the MRC AML10 trial and the SWOG/ECOG trial have analyzed patient outcomes based on cytogenetic risk groups. In the MRC AML10 trial the advantage for autologous transplantation vs consolidation chemotherapy was maintained in all three cytogenetic risk groups. Whether patients had favorable, intermediate, or unfavorable cytogenetics they had improved disease-free survival if treated in first remission with chemotherapy followed by autologous transplantation compared to receiving chemotherapy alone. 10 In the ECOG/SWOG study the results were somewhat different. 13 Among those with favorable cytogenetics, there was a benefit for autologous or allogeneic transplantation compared to chemotherapy. In the intermediate cytogenetics group, there was no difference between chemotherapy and allogeneic Leukemia transplantation but, somewhat surprisingly, both groups did better than the group treated with autologous transplantation. For the unfavorable cytogenetic risk group patients, the allogeneic arm was the only treatment that did reasonably well with a 40% cure rate at 5 years, while those treated with autologous transplantation or chemotherapy did poorly.
Taken together and acknowledging their weaknesses, these four studies would generally suggest that patients with highrisk disease should be treated with allogeneic transplantation if at all possible. Allogeneic transplantation from a matched sibling can also be recommended for the majority of the other patients, although the comparative benefits of transplantation in first remission over a strategy of chemotherapy first, followed by transplantation at first relapse may be relatively small for patients with intermediate or good risk cytogenetics. Autologous transplantation is not a substitute for intensive consolidation chemotherapy, but may prolong diseasefree survival and overall survival if applied after intensive consolidation.
Whether or not there are patients who should be transplanted as initial therapy without any attempt at initial induction is unclear. One group that may be candidates for such a strategy is patients with secondary AML following a prior history of myelodysplasia. Such patients have a limited chance of achieving an initial complete remission with standard chemotherapy and may have relatively low blast counts at the time of transplantation. A study in Seattle attempted to address this question and found a 25% cure rate in patients with secondary AML transplanted without initial induction.
14 In a nonrandomized but contemporaneous control group who received prior induction chemotherapy, the outcome was not improved. The question of whether a strategy of initial transplantation is better than a strategy of chemotherapy first followed by transplantation for such patients would best be addressed in a prospective, randomized trial.
